登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：688148 证券简称：芳源股份 公告编号：2026-011 转债代码：118020 转债简称：芳源转债 广东芳源新材料集团股份有限公司 关于"芳源转债"预计触发转股价格向下修正条件的提示性公告 2、2025年12月12日至2026年1月5日，因触发"芳源转债"转股价格向下修正条款，根据《募集说明书》 的相关条款规定以及2026年第一次临时股东会的授权，公司于2026年1月21日召开第四届董事会第九次 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性依法承担法律责任。 特别提示： ● 2026年1月23日至2026年2月5日，公司股票在连续30个交易日中已有10个交易日的收盘价低于当期转 股价格的85%（即11.90元/股），预计触发转股价格向下修正条件。若触发条件，公司将于触发条件当 日召开董事会审议决定是否修正转股价格，并及时履行信息披露义务。敬请广大投资者注意投资风险。 一、可转换公司债券基本情况 （一）发行上市情况 经中国证券监督管理委员会出具的《关于同意广东芳源新材料集团股 ...

| 证券代码：688148 | 证券简称：芳源股份 | 公告编号：2026-011 | | --- | --- | --- | | 转债代码：118020 | 转债简称：芳源转债 | | 广东芳源新材料集团股份有限公司 关于"芳源转债"预计触发转股价格向下修正条件的 提示性公告 募集资金人民币 64,200.00 万元。本次发行的可转换公司债券的期限为自发行之 日起六年，即自 2022 年 9 月 23 日至 2028 年 9 月 22 日。 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 特别提示： 2026 年 1 月 23 日至 2026 年 2 月 5 日，公司股票在连续 30 个交易日中 已有 10 个交易日的收盘价低于当期转股价格的 85%（即 11.90 元/股），预计触 发转股价格向下修正条件。若触发条件，公司将于触发条件当日召开董事会审议 决定是否修正转股价格，并及时履行信息披露义务。敬请广大投资者注意投资风 险。 一、可转换公司债券基本情况 （一）发行上市情况 经中国证券监督管理委员会出具的《关于同意广 ...

1 中证鹏元资信评估股份有限公司 中证鹏元公告【2026】63 号 中证鹏元关于关注广东芳源新材料集团股份有限公司 2025 年年度业绩预亏事项的公告 中证鹏元资信评估股份有限公司（以下简称"中证鹏元"）对广 东芳源新材料集团股份有限公司（以下简称"芳源股份"或"公司"， 股票代码：688148.SH）及其发行的下述债券开展评级。除评级委托 关系外，中证鹏元及评级从业人员与公司不存在任何足以影响评级行 为独立、客观、公正的关联关系。 | 债券简称 | 上一次评级时间 | | | | | | 上一次评级结果 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | | | | 主体等级 债项等级 | | | 评级展望 | | 芳源转债 | 2025 年 9 | 月 | 4 | 日 | | BBB | BBB | 稳定 | 公司于 2026 年 1 月 30 日披露《广东芳源新材料集团股份有限公 司 2025 年年度业绩预告》，预计 2025 年年度实现归属母公司所有者 的净利润为-1.20 亿元到-0.80 亿元，亏损同比大幅收窄（上年同 ...

| 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | --- | --- | --- | --- | --- | --- | | 688148 | 芳源股份 | 8.20 | -6.29% | 20.26万 | 1.70亿 | | 300919 | 中伟新材 | 51.59 | -5.81% | 23.33万 | 12.32 Z | | 301662 | 宏 科技 | 164.73 | -5.73% | ● 1.10万 | 1.86 亿 | | 002340 | 格林美 | 8.45 | -5.69% | 266.90万 | 23.05亿 | | 688339 | 亿华通 | 29.25 | -5.43% | 5.74万 | 1.72亿 | | 688778 | 厦钨新能 | 81.84 | -5.17% | 5.75万 | 4.81亿 | | 300769 | 德方纳米 | 39.30 | -5.07% | 13.77万 | 5.53亿 | | 688275 | 万润新能 | 73.10 | -5.02% | 4.20万 | 3.16亿 | | 301217 | 铜冠铜箔 ...

广东芳源新材料集团股份有限公司2025年年度业绩预告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性依法承担法律责任。 一、本期业绩预告情况 证券代码：688148 证券简称：芳源股份 公告编号：2026-010 （一）业绩预告期间 转债代码：118020 转债简称：芳源转债 2025年1月1日至2025年12月31日 （二）业绩预告情况 二、上年同期业绩情况和财务状况 （一）利润总额：-39,041.08万元。归属于母公司所有者的净利润：-42,677.47万元。归属于母公司所有 者的扣除非经常性损益的净利润：-44,275.30万元。 （二）每股收益：-0.85元/股 三、本期业绩变化的主要原因 公司预计2025年将出现亏损，但亏损同比大幅收窄，主要原因如下： 1、2025年上半年，公司积极推动多元化转型及产线升级改造导致产生停工损失，碳酸锂市场价格走低 导致原材料供应出现阶段性减少，综合影响下公司上半年产能利用率偏低、部分产品单位成本较高，综 合毛利率下降，导致公司上半年出现大额亏损。 2、2025年公司实现了新一代回收料分离提纯新技 ...

Earnings Forecasts - Shengyi Electronics expects a net profit of 1.431 billion to 1.513 billion yuan in 2025, an increase of 331.03% to 355.88% year-on-year [1] - Tigermed anticipates a net profit of 830 million to 1.23 billion yuan in 2025, representing a growth of 105% to 204% year-on-year [2] - Shunbo Alloy forecasts a net profit of 210 million to 270 million yuan in 2025, with an increase of 222.96% to 315.23% year-on-year [3] - Jinkong Electric expects a net profit of 155 million to 195 million yuan in 2025, reflecting a growth of 383.21% to 507.9% year-on-year [9] - Baiao Saitu anticipates a net profit of 162 million to 182 million yuan in 2025, with a year-on-year increase of 384.26% to 443.88% [18] - Panjiang Co. expects a net profit of 318 million to 380 million yuan in 2025, representing a growth of 205.30% to 264.83% year-on-year [38] Loss Forecasts - Liaoning Energy predicts a net loss of 273 million to 410 million yuan in 2025, compared to a profit of 202 million yuan in the previous year [5] - Anbotong anticipates a net loss of 114 million to 165 million yuan in 2025, with a revenue decrease of 19.65% to 27.25% [7] - Wantai Bio forecasts a net loss of 330 million to 410 million yuan in 2025, compared to a profit of 106 million yuan in the previous year [12] - Xingyun Co. expects a net loss of 155 million to 230 million yuan in 2025, compared to a loss of 82.44 million yuan in the previous year [20] - Huaxing Co. anticipates a net loss of 800 million to 1.2 billion yuan in 2025, with a reduction in loss compared to 1.67 billion yuan in the previous year [46] New Product Approvals - Hengrui Medicine received acceptance for a new indication application for its innovative drug, combining Carrelizumab and Apatinib for treating unresectable liver cancer [4] - Tianen Kang's subsidiary received a drug registration acceptance notice for Lidocaine and Prilocaine aerosol [31] - Lisheng Pharmaceutical announced that its Aminophylline tablets passed the consistency evaluation for generic drugs [40] Share Buyback Plans - Hengyuan Coal Power plans to repurchase shares with a total amount not less than 200 million yuan and not exceeding 250 million yuan [13] Contract Wins - China Communication Signal Co. won contracts totaling approximately 5.26 billion yuan for 21 important projects in the railway and urban rail transit markets [37]

Core Viewpoint - The company is expected to report a net loss of 80 million to 120 million yuan for the year 2025, indicating a significant decline compared to the previous year [1] Group 1: Financial Performance - The company anticipates a net loss attributable to shareholders of 80 million to 120 million yuan for 2025, compared to the previous year's statutory disclosure data [1] - In the first half of 2025, the company faced operational challenges due to diversification efforts and production line upgrades, leading to work stoppage losses and a low capacity utilization rate [1] - The decline in lithium carbonate market prices resulted in a temporary reduction in raw material supply, contributing to higher unit costs for some products and a decrease in overall gross margin [1] Group 2: Technological Advancements and Market Recovery - The company successfully scaled the application of a new generation of recycling material separation and purification technology in 2025, utilizing battery waste and nickel-cobalt-lithium recycling materials [2] - The company increased the proportion of recycled raw materials and promoted the application of new technologies in the second half of 2025, leading to a significant increase in the shipment volume of precursor products and nickel, cobalt, manganese, and lithium salt products [2] - Starting from the third quarter, metal prices, particularly cobalt prices, have been rising, which has positively impacted product sales prices and significantly improved product gross margins [2]

公司预计2025年将出现亏损，但亏损同比大幅收窄，主要原因如下：2025年上半年，公司积极推动多元 化转型及产线升级改造导致产生停工损失，碳酸锂市场价格走低导致原材料供应出现阶段性减少，综合 影响下公司上半年产能利用率偏低、部分产品单位成本较高，综合毛利率下降，导致公司上半年出现大 额亏损。 格隆汇1月29日丨芳源股份(688148.SH)公布，经财务部门初步测算，公司预计2025年年度实现归属于母 公司所有者的净利润与上年同期（法定披露数据）相比，将出现亏损，实现归属于母公司所有者的净利 润-12,000.00万元到-8,000.00万元。公司预计2025年年度实现归属于母公司所有者扣除非经常性损益后 的净利润-11,700.00万元到-7,800.00万元。 ...

Core Viewpoint - Fangyuan Co., Ltd. expects a net loss attributable to shareholders of 80 million to 120 million yuan for the fiscal year 2025, an improvement from a loss of 427 million yuan in the same period last year [1] Group 1: Financial Performance - The company anticipates a net profit loss of 80 million to 120 million yuan for 2025, compared to a loss of 427 million yuan in the previous year [1] - The company has seen a significant reduction in the balance of inventory impairment provisions year-on-year, contributing to improved operational performance [1] Group 2: Product and Sales Performance - In the second half of 2025, the company has been increasing the proportion of recycled raw materials and promoting the application of new technologies, including high-nickel binary precursors and cobalt sulfate, leading to a continuous increase in product output [1] - The total shipment of precursor products reached approximately 11,200 tons for the year, while the total shipment of nickel, cobalt, manganese, and lithium salt products (including processing) was about 41,700 tons, with year-on-year growth in both categories [1] Group 3: Market Conditions - Since the third quarter, metal prices, particularly cobalt prices, have been on the rise, resulting in a corresponding increase in product sales prices and a significant improvement in product gross margins [1] - The revenue recognition from technology export cooperation projects has also positively impacted the company's financial performance [1]

芳源股份公告称，预计2025年年度归属于母公司所有者的净利润为-1.20亿元到-0.80亿元，上年同期 为-4.27亿元；扣非净利润为-1.17亿元到-0.78亿元，上年同期为-4.43亿元。2025年上半年公司因转型改 造等因素亏损，下半年新技术规模化应用，产品出货量增长，金属价格上涨使毛利率提升，叠加存货跌 价准备减少等因素，下半年扭亏为盈，全年亏损幅度大幅收窄。 ...